Selvita (WSE:SLV) Third Quarter 2023 Results
Key Financial Results
- Revenue: zł84.1m (down 23% from 3Q 2022).
- Net loss: zł4.27m (down by 148% from zł8.99m profit in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Selvita Earnings Insights
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Poland.
The company's shares are up 2.9% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Selvita's balance sheet.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:SLV
Solid track record with reasonable growth potential.
